Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03708627 · ClinicalTrials.gov registry record · Early Phase 1
Bimatoprost as a Treatment for Graves' Orbitopathy
A Early Phase 1 study of Graves Ophthalmopathy, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT03708627 is a Early Phase 1 study of Graves Ophthalmopathy that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 3 participants, below the 88-participant average among 3 other Graves Ophthalmopathy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03708627, a Early Phase 1 study of Graves Ophthalmopathy, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
Conditions Studied
Interventions
- DRUG Bimatoprost Ophthalmic
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2031-07-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03708627
The ClinicalTrials.gov registry entry for NCT03708627 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 3 other Graves Ophthalmopathy trials with a reported enrollment target (97% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Graves Ophthalmopathy appearing as the primary indexed condition, and to 1 intervention - of which Bimatoprost Ophthalmic is the first listed.
NCT03708627 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT03708627 about?
NCT03708627 is a clinical study titled "Bimatoprost as a Treatment for Graves' Orbitopathy". Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
What is the current status of trial NCT03708627?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2017-11-01. Estimated completion is 2031-07-01.
What conditions does trial NCT03708627 study?
This clinical trial studies the following conditions: Graves Ophthalmopathy.
What interventions are being tested in trial NCT03708627?
The interventions under investigation include: Bimatoprost Ophthalmic (DRUG).
Who is sponsoring clinical trial NCT03708627?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03708627 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graves Ophthalmopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RECRUITING
-
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.